AMS Biotechnology Ltd / Ligand / M Ab / Charles River Laboratories / /
Country
Germany / United States / United Kingdom / / /
Facility
University of Manchester / Royal Liverpool University Hospital / Netherland Cancer Institute / The Netherlands Cancer Institute / University of Liverpool / Institute of Translational Medicine / /
IndustryTerm
cultured media / cancer therapy / animal care protocol / culture media / cancer tissue bank / chemicals / /
MedicalCondition
4T1 breast cancer / colorectal cancer / metastasis / colon cancers / only localised tumours / colon cancer / melanoma / human melanoma ACA19 / colon and breast cancer / head and neck cancer / prostate cancer / otherwise non-metastatic breast cancer / lung metastases / breast cancer / breast and colorectal cancer / CTBRC cancer / breast tumours / cancers / cancer metastasis / human colon cancer LS174T / breast cancers / inflammatory regulators / Cancer / liver metastasis / conditioned medium-induced cancer cell adhesion / consequently cytokine-mediated metastasis / primary tumours / metastasis C Chen1 / HCT116 cancer / tumour / lung metastasis / BRITISH JOURNAL OF CANCER / increase cancer / melanoma tumours / breast and colon cancer / urothelial cancer / MUC1-negative HCT116 human colon cancer / colon cancer HCT116 cells / cancer BRITISH JOURNAL OF CANCER / increased cancer / colon tumours / tumours / /
MedicalTreatment
chemo / cancer therapy / /
Organization
University of Liverpool / Liverpool / University of Manchester / Manchester / The Netherlands Cancer Institute / Royal Liverpool University Hospital / Medical Research Council / Institute of Translational Medicine / Department of Gastroenterology / Netherland Cancer Institute / European Union / Bio-Rad Image Lab / Local Research Ethics Committee / /
Person
Wang / Chin / John Hilkens / /
Position
Representative / /
Product
IL-6 / M-16 / /
PublishedMedium
BRITISH JOURNAL OF CANCER / /
RadioStation
C AM / 1 Calcein AM / Calcein AM / /
Technology
alpha / antibodies / animal care protocol / treating cancer / 3G / /
BJC_COVER_VOL_105_NO_7.indd